These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30004800)

  • 1. Transplantation in highly sensitized patients: challenges and recommendations.
    Heidt S; Claas FHJ
    Expert Rev Clin Immunol; 2018 Aug; 14(8):673-679. PubMed ID: 30004800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly Sensitized Patients Are Well Served by Receiving a Compatible Organ Offer Based on Acceptable Mismatches.
    Heidt S; Haasnoot GW; van der Linden-van Oevelen MJH; Claas FHJ
    Front Immunol; 2021; 12():687254. PubMed ID: 34248971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients.
    Heidt S; Haasnoot GW; van Rood JJ; Witvliet MD; Claas FHJ
    Kidney Int; 2018 Feb; 93(2):491-500. PubMed ID: 28947279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplantation of the broadly sensitized patient: what are the options?
    Böhmig GA; Wahrmann M; Bartel G
    Curr Opin Organ Transplant; 2011 Dec; 16(6):588-93. PubMed ID: 21971512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extending options for highly sensitized patients to receive a suitable kidney graft.
    Doxiadis II; Duquesnoy RJ; Claas FH
    Curr Opin Immunol; 2005 Oct; 17(5):536-40. PubMed ID: 16084709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How the definition of acceptable antigens and epitope analysis can facilitate transplantation of highly sensitized patients with excellent long-term graft survival.
    Heidt S; Haasnoot GW; Claas FHJ
    Curr Opin Organ Transplant; 2018 Aug; 23(4):493-499. PubMed ID: 29846197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both.
    Doxiadis II; Claas FH
    Curr Opin Organ Transplant; 2009 Aug; 14(4):410-3. PubMed ID: 19417658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group.
    Mamode N; Bestard O; Claas F; Furian L; Griffin S; Legendre C; Pengel L; Naesens M
    Transpl Int; 2022; 35():10511. PubMed ID: 36033645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the Canadian allocation system for highly sensitized patients work?
    Aleksova N; Ross HJ
    Curr Opin Organ Transplant; 2019 Jun; 24(3):239-244. PubMed ID: 31090630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Europe wide acceptable mismatch program will enable transplantation of long waiting highly sensitised patients with a compatible donor.
    Mumford L; Fuggle SV; Martorell J; Slavcev A; Iniotaki A; Haasnoot GW; Heidt S; Claas FHJ
    Transpl Immunol; 2021 Feb; 64():101354. PubMed ID: 33276060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney transplantation of highly sensitized recipients under the new kidney allocation system: A reflection from five different transplant centers across the United States.
    Parsons RF; Locke JE; Redfield RR; Roll GR; Levine MH
    Hum Immunol; 2017 Jan; 78(1):30-36. PubMed ID: 27773831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of the highly sensitized patient.
    Claas FH; Doxiadis II
    Curr Opin Immunol; 2009 Oct; 21(5):569-72. PubMed ID: 19682882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calculated panel reactive antibody with decimals: A refined metric of access to transplantation for highly sensitized candidates.
    Kransdorf EP; Pando MJ
    Hum Immunol; 2017 Mar; 78(3):252-256. PubMed ID: 28069404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of the frequency of anti-HLA hyperimmunization in patients with kidney transplantation].
    Pongratz G; Goumaz C; Gore SM; Bradley BA; Jeannet M
    Schweiz Med Wochenschr; 1990 Sep; 120(37):1335-8. PubMed ID: 2218455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney transplantation across HLA and ABO antibody barriers.
    Becker LE; Süsal C; Morath C
    Curr Opin Organ Transplant; 2013 Aug; 18(4):445-54. PubMed ID: 23838650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients.
    Montgomery RA; Lonze BE; Jackson AM
    Curr Opin Organ Transplant; 2011 Aug; 16(4):439-43. PubMed ID: 21666478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approach to the Highly Sensitized Kidney Transplant Candidate.
    Keith DS; Vranic GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):684-93. PubMed ID: 26915916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceptable HLA mismatches for highly immunized patients.
    Claas FH; De Meester J; Witvliet MD; Smits JM; Persijn GG; Doxiadis II
    Rev Immunogenet; 1999; 1(3):351-8. PubMed ID: 11256426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA compatibility assessment and management of highly sensitized patients under the new kidney allocation system (KAS): A 2016 status report from twelve HLA laboratories across the U.S.
    Kamoun M; Phelan D; Noreen H; Marcus N; Klingman L; Gebel HM
    Hum Immunol; 2017 Jan; 78(1):19-23. PubMed ID: 27840088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates.
    Duquesnoy RJ; Witvliet M; Doxiadis II; de Fijter H; Claas FH
    Transpl Int; 2004 Jan; 17(1):22-30. PubMed ID: 12955350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.